The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease

Journal of Parkinson's Disease

Volumn 7, Issue 3, 2017, Pages 433-450

  Galvagnion, Céline ^a,b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

amyloid; cholesterol; fatty acids; glucocerebrosidase; kinetic analysis; lipids; Parkinson's disease; sphingolipid; synuclein

Indexed keywords

ALPHA SYNUCLEIN; CHOLESTEROL; FATTY ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LIVER X RECEPTOR; OLEIC ACID; PHOSPHOLIPID; SPHINGOLIPID; STEARIC ACID; UNSATURATED FATTY ACID; MEMBRANE LIPID;

APOPTOSIS; BRAIN CELL; CELL PROLIFERATION; DOPAMINERGIC NERVE CELL; ENDOSOME; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; LIPID VESICLE; NERVE CELL; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PH; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPHINGOLIPID METABOLISM; ANIMAL; CHEMISTRY; METABOLISM; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; MEMBRANE LIPIDS; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 85027401319     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-171103     Document Type: Review

References (109)

1. Maroteaux L, Campanelli JT, & Scheller RH (1988) Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 8, 2804-2815.
2. Spillantini MG, & amp; Goedert M (2000) The alphasynucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci, 920, 16-27.
3. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, & amp; Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
4. Burré J (2015) The synaptic function of synuclein. J Parkinsons Dis, 5, 699-713.
5. Burré J, Sharma M, TsetsenisT, BuchmanV, EthertonMR, & amp; Südhof TC (2010) Alpha-synuclein promotes SNARE complex assembly in vivo and in vitro. Science, 329, 1663-1667.
6. Takamori S, Holt M, Stenius K, Lemke EA, Grønborg M, Riedel D, Urlaub H, Schenck S, Brügger B, Ringler P, Müller SA, Rammner B, Gräter F, Hub JS, De Groot BL, Mieskes G, Moriyama Y, Klingauf J, Grubmüller H, Heuser J,Wieland F, & amp; Jahn R (2006) Molecular anatomy of a trafficking organelle. Cell, 127, 831-846.
7. van Meer G, Voelker DR, & amp; Feigenson GW (2008) Membrane lipids: Where they are and how they behave. Nat Rev Mol Cell Biol, 9, 112-124.
8. Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, Spener F, vanMeer G,Wakelam MJ, Dennis EA (2009) Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res 50(Suppl), S9-14.
9. Bodner CR, Dobson CM, & amp; Bax A (2009) Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. J Mol Biol, 390, 775-790.
10. Chandra S, Chen X, Rizo J, Jahn R, & amp; Südhof TC (2003) A broken alpha-helix in folded alpha-synuclein. J Biol Chem, 278, 15313-15318.
11. Fusco G, De Simone A, Gopinath T, Vostrikov V, Vendruscolo M, Dobson CM, & amp; Veglia G (2014) Direct observation of the three regions in synuclein that determine its membrane-bound behaviour. Nat Commun, 5, 3827.
12. Hellstrand E, Grey M, Ainalem ML, Ankner J, Forsyth VT, Fragneto G, Haertlein M, Dauvergne MT, Nilsson H, Brundin P, Linse S, Nylander T, & Sparr E (2013) Adsorption of synuclein to supported lipid bilayers: Positioning and role of electrostatics. ACS Chem Neurosci, 4, 1339-1351.
13. Pfefferkorn CM, Heinrich F, Sodt AJ, Maltsev AS, Pastor RW, & amp; Lee JC (2012) Depth of synuclein in a bilayer determined by fluorescence, neutron reflectometry, and computation. Biophys J, 102, 613-621.
14. Fusco G, De Simone A, Arosio P, Vendruscolo M, Veglia G, & amp; Dobson CM (2016) Structural ensembles of membrane-bound synuclein reveal the molecular determinants of synaptic vesicle affinity. Sci Rep, 6, 27125.
15. Jo E, McLaurin J, Yip CM, St George-Hyslop P, & amp; Fraser PE (2000) alpha-synuclein membrane interactions and lipid specificity. J Biol Chem, 275, 34328-34334.
16. Davidson WS, Jonas A, Clayton DF, & amp; George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem, 273, 9443-9449.
17. Pantusa M, Vad B, Lillelund O, Kjær L, Otzen D, & amp; Bartucci R (2016) Alpha-synuclein and familial variants affect the chain order and the thermotropic phase behavior of anionic lipid vesicles. Biochim Biophys Acta, 1864, 1206-1214.
18. Pirc K, & amp; Ulrih NP (2015) Synuclein interactions with phospholipid model membranes: Key roles for electrostatic interactions and lipid-bilayer structure. Biochim Biophys Acta, 1848, 2002-2012.
19. Galvagnion C, BrownJW, OuberaiMM,Flagmeier P,Vendruscolo M, Buell AK, Sparr E, & amp; Dobson CM (2016) Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of synuclein. Proc Natl Acad Sci U S A, 113, 7065-7070.
20. Westphal CH, & amp; Chandra SS (2013) Monomeric synucleins generate membrane curvature. J Biol Chem, 288, 1829-1840.
21. Pandey AP, Haque F, Rochet JC, & amp; Hovis JS (2011) Synuclein-induced tubule formation in lipid bilayers. J Phys Chem B, 115, 5886-5893.
22. Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss JC, Stamou DG, Steven AC, & amp; Langen R (2010) Membrane curvature induction and tabulation are common features of synucleins and apolipoproteins. J Biol Chem, 285, 32486-32493.
23. Jiang Z, de Messieres M, & amp; Lee JC (2013) Membrane remodeling by synuclein and effects on amyloid formation. J Am Chem Soc, 135, 15970-15973.
24. Shi Z, Sachs JN, Rhoades E, & amp; Baumgart T (2015) Biophysics of synuclein induced membrane remodelling. Phys Chem Chem Phys, 17, 15561-15568.
25. Braun AR, Lacy MM, Ducas VC, Rhoades E, & amp; Sachs JN (2014) Synuclein-induced membrane remodeling is driven by binding affinity, partition depth, and interleaflet order asymmetry. J Am Chem Soc, 136, 9962-9972.
26. Ouberai MM, Wang J, Swann MJ, Galvagnion C, Guilliams T, Dobson CM, & Welland ME (2013) Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J Biol Chem, 288, 20883-20895.
27. Garten M, Prévost C, Cadart C, Gautier R, Bousset L, Melki R, Bassereau P, & amp; Vanni S (2015) Methyl-branched lipids promote the membrane adsorption of synuclein by enhancing shallow lipid-packing defects. Phys Chem Chem Phys, 17, 15589-15597.
28. Galvagnion C, Buell AK, Meisl G, Michaels TC,Vendruscolo M, Knowles TP, & amp; Dobson CM (2015) Lipid vesicles trigger synuclein aggregation by stimulating primary nucleation. Nat Chem Biol, 11, 229-234.
29. Rhoades E, Ramlall TF, Webb WW, & amp; Eliezer D (2006) Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys J, 90, 4692-4700.
30. Zhu M, Li J, & amp; Fink AL (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem, 278, 40186-40197.
31. Jo E, Fuller N, Rand RP, St George-Hyslop P, & amp; Fraser PE (2002) Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol Biol, 315, 799-807.
32. Perni M, Galvagnion C, Maltsev A, Meisl G, Müller MB, Challa PK, Kirkegaard JB, Flagmeier P, Cohen SI, Cascella R, Chen SW, Limboker R, Sormanni P, Heller GT, Aprile FA, Cremades N, Cecchi C, Chiti F, Nollen EA, Knowles TP, Vendruscolo M, Bax A, Zasloff M, & amp; Dobson CM (2017) A natural product inhibits the initiation of synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci U S A, 114, E1009-E1017.
33. Brown JW, Buell AK, Michaels TC, Meisl G, Carozza J, Flagmeier P, Vendruscolo M, Knowles TP, Dobson CM, & Galvagnion C (2016) Synuclein suppresses both the initiation and amplification steps of synuclein aggregation via competitive binding to surfaces. Sci Rep, 6, 36010.
34. Burré J, Sharma M, & amp; Südhof TC (2015) Definition of a molecular pathway mediating synuclein neurotoxicity. J Neurosci, 35, 5221-5232.
35. GreyM, Dunning CJ, Gaspar R, Grey C, Brundin P, Sparr E, & amp; Linse S (2015) Acceleration of synuclein aggregation by exosomes. J Biol Chem, 290, 2969-2982.
36. Broersen K, van den Brink D, Fraser G, Goedert M, & amp; Davletov B (2006) Alpha-synuclein adopts an alpha helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation. Biochemistry, 45, 15610-15616.
37. Martinez Z, Zhu M, Han S, & amp; Fink AL (2007) GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry, 46, 1868-1877.
38. De Franceschi G, Frare E, Pivato M, Relini A, Penco A, Greggio E, Bubacco L, Fontana A, & de Laureto PP (2011) Structural and morphological characterization of aggregated species of synuclein induced by docosahexaenoic acid. J Biol Chem, 286, 22262-22274.
39. Sharon R, Bar-Joseph I, Frosch MP,Walsh DM, Hamilton JA, & amp; Selkoe DJ (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 37, 583-595.
40. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, & amp; Krainc D (2011) Gaucher disease glucocerebrosidase and synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146, 37-52.
41. Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, & amp; Schapira AH (2016) Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: Relevance to Parkinson disease. Hum Mol Genet, 25, 3432-3445.
42. Prence EM, Chaturvedi P, & amp; Newburg DS (1996) In vitro accumulation of glucocerebroside in neuroblastoma cells: A model for study of Gaucher disease pathobiology. J Neurosci Res, 43, 365-371.
43. Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, & amp; Kelly JW (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol, 2, 249-253.
44. Yang SY, Beavan M, Chau KY, Taanman JW, & amp; Schapira AH (2017) A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers. Stem Cell Reports, 8, 728-742.
45. Schöndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, Sardi SP, Valsecchi M, Hoffmann S, Schwarz LK, Hedrich U, Berg D, Shihabuddin LS, Hu J, Pruszak J, Gygi SP, Sonnino S, Gasser T, & amp; Deleidi M (2014) iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun, 5, 4028.
46. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, & amp; Selkoe DJ (2003) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem, 278, 49874-49881.
47. Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, Schoenen FJ, Westbroek W, Zheng W, Sullivan P, Fujiwara H, Sidhu R, Khaliq ZM, Lopez GJ, Goldstein DS, Ory DS, Marugan J, & amp; Sidransky E (2016) A new glucocerebrosidase chaperone reduces synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J Neurosci, 36, 7441-7452.
48. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, & amp; Schapira AH (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol, 72, 455-463.
49. Bartels T, Kim NC, Luth ES, & Selkoe DJ (2014) N-alphaacetylation of synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One, 9, e103727.
50. Eichmann C, Campioni S, Kowal J, Maslennikov I, Gerez J, Liu X,Verasdonck J, Nespovitaya N, Choe S, Meier BH, Picotti P, Rizo J, Stahlberg H, & amp; Riek R (2016) Preparation and characterization of stable synuclein lipoprotein particles. J Biol Chem, 291, 8516-8527.
51. Varkey J, Mizuno N, Hegde BG, Cheng N, Steven AC, & amp; Langen R (2013) Synuclein oligomers with broken helical conformation form lipoprotein nanoparticles. J Biol Chem, 288, 17620-17630.
52. Fecchio C, De Franceschi G, Relini A, Greggio E, Dalla Serra M, Bubacco L, & amp; Polverino de Laureto P (2013) Synuclein oligomers induced by docosahexaenoic acid affect membrane integrity. PLoS One, 8, e82732.
53. Suzuki M, Fujikake N, Takeuchi T, Kohyama-Koganeya A, Nakajima K, HirabayashiY,Wada K, & NagaiY(2015) Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet, 24, 6675-6686.
54. Perrin RJ, Woods WS, Clayton DF, & amp; George JM (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem, 276, 41958-41962.
55. Hellstrand E, Nowacka A, Topgaard D, Linse S, & Sparr E (2013) Membrane lipid co-aggregation with synuclein fibrils. PLoS One, 8, e77235.
56. Marsh D (2013) Handbook of Lipid Bilayers, CRC Press, Boca Raton, F.L.
57. Haque F, Pandey AP, Cambrea LR, Rochet JC, & amp; Hovis JS (2010) Adsorption of alpha-synuclein on lipid bilayers: Modulating the structure and stability of protein assemblies. J Phys Chem B, 114, 4070-4081.
58. Pandey AP, Haque F, Rochet JC, & amp; Hovis JS (2009) Clustering of alpha-synuclein on supported lipid bilayers: Role of anionic lipid, protein, and divalent ion concentration. Biophys J, 96, 540-551.
59. Wilhelm BG, Mandad S, Truckenbrodt S, Kröhnert K, Schäfer C, Rammner B, Koo SJ, Claßen GA, Krauss M, Haucke V, Urlaub H, & amp; Rizzoli SO (2014) Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science, 344, 1023-1028.
60. Campioni S, Carret G, Jordens S, Nicoud L, Mezzenga R, & amp; Riek R (2014) The presence of an air-water interface affects formation and elongation of Synuclein fibrils. J Am Chem Soc, 136, 2866-2875.
61. Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, Vendruscolo M, Terentjev EM, Welland ME, & amp; Dobson CM (2009) An analytical solution to the kinetics of breakable filament assembly. Science, 326, 1533-1537.
62. Grey M, Linse S, Nilsson H, Brundin P, & amp; Sparr E (2011) Membrane interaction of synuclein in different aggregation states. J Parkinsons Dis, 1, 359-371.
63. Gaspar R, Meisl G, Buell AK, Young L, Kaminski CF, Knowles TP, Sparr E, & amp; Linse S (2017) Secondary nucleation of monomers on fibril surface dominates (-synuclein aggregation and provides autocatalytic amyloid amplification. Q Rev Biophys, 50, e6.
64. Vácha R, Linse S, & amp; Lund M (2014) Surface effects on aggregation kinetics of amyloidogenic peptides. J Am Chem Soc, 136, 11776-11782.
65. Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TP, Linse S, & amp; Dobson CM (2014) Solution conditions determine the relative importance of nucleation and growth processes in synuclein aggregation. Proc Natl Acad Sci U S A, 111, 7671-7676.
66. Arosio P, Vendruscolo M, Dobson CM, & amp; Knowles TP (2014) Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol Sci, 35, 127-135.
67. Zhu M, & amp; Fink AL (2003) Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem, 278, 16873-16877.
68. Ruipérez V, Darios F, & amp; Davletov B (2010) Alphasynuclein, lipids and Parkinson's disease. Prog Lipid Res, 49, 420-428.
69. Iljina M, Tosatto L, Choi ML, Sang JC, Ye Y, Hughes CD, Bryant CE, Gandhi S, & KlenermanD(2016) Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein. Sci Rep, 6, 33928.
70. De Franceschi G, Fecchio C, Sharon R, Schapira AHV, Proukakis C, Bellotti V, & amp; de Laureto PP (2017) Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. J Biol Chem, 292, 6927-6937.
71. Manning-Bo?g AB, Schüle B, & amp; Langston JW (2009) Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism. Neurotoxicology, 30, 1127-1132.
72. Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M, Wood NW, Hardy J, Mark Cooper J, & amp; Schapira AH (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int, 62, 1-7.
73. Assayag K, Yakunin E, Loeb V, Selkoe DJ, & amp; Sharon R (2007) Polyunsaturated fatty acids induce alphasynuclein-related pathogenic changes in neuronal cells. Am J Pathol, 171, 2000-2011.
74. Karube H, Sakamoto M, Arawaka S, Hara S, Sato H, Ren CH, Goto S, Koyama S,Wada M, Kawanami T, Kurita K, & amp; Kato T (2008) N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules. FEBS Lett, 582, 3693-3700.
75. Darios F, Ruipérez V, Ĺopez I, Villanueva J, Gutierrez LM, & amp; Davletov B (2010) Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis. EMBO Rep, 11, 528-533.
76. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & amp; Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
77. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M,Waucquier N, Defebvre L, Amouyel P, Farrer M, & amp; Destée A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169.
78. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, & amp; Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66-79.
79. Beavan MS, & amp; Schapira AH (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med, 45, 511-521.
80. Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet, 372, 1263-1271.
81. Beutler E, Grabowski GA (2001) The Metabolic and Molecular Basis of Inherited Disease, McGraw-Hill, New York, pp. 3635-3668.
82. Xu YH, Quinn B, Witte D, & amp; Grabowski GA (2003) Viable mouse models of acid beta-glucosidase deficiency: The defect in Gaucher disease. Am J Pathol, 163, 2093-2101.
83. Sun Y, Quinn B, Witte DP, & amp; Grabowski GA (2005) Gaucher disease mouse models: Point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res, 46, 2102-2113.
84. XuYH, SunY, Ran H, Quinn B,Witte D, & GrabowskiGA (2011) Accumulation and distribution of synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab, 102, 436-447.
85. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P,Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, & amp; Schlossmacher MG (2011) Acid glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter synuclein processing. Ann Neurol, 69, 940-953.
86. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, & amp; Shihabuddin LS (2011) CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucherrelated synucleinopathy. Proc Natl Acad Sci U S A, 108, 12101-12106.
87. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, & amp; Duchen MR (2013) Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab, 17, 941-953.
88. Rantham Prabhakara JP, Feist G, Thomasson S, Thompson A, Schommer E, & amp; Ghribi O (2008) Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells. J Neurochem, 107, 1722-1729.
89. Migdalska-Richards A, Daly L, Bezard E, & amp; Schapira AH (2016) Ambroxol effects in glucocerebrosidase and synuclein transgenic mice. Ann Neurol, 80, 766-775.
90. Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH, Levy OA, Xu Y, Shim HB, Pe'er I, Di Paolo G, & amp; Alcalay RN (2017) Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis. PLoS One, 12, e0172348.
91. Ron I, & amp; Horowitz M (2008) Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients. Mol Genet Metab, 93, 426-436.
92. Salvioli R, Tatti M, Scarpa S, Moavero SM, Ciaffoni F, Felicetti F, Kaneski CR, Brady RO, & amp; Vaccaro AM (2005) The N370S (Asn370->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. Biochem J, 390, 95-103.
93. Sillence DJ, Puri V, Marks DL, Butters TD, Dwek RA, Pagano RE, & amp; Platt FM (2002) Glucosylceramide mod ulates membrane traffic along the endocytic pathway. J Lipid Res, 43, 1837-1845.
94. Takahashi Y, Nada S, Mori S, Soma-Nagae T, Oneyama C, & amp; Okada M (2012) The late endosome/lysosomeanchored p18-mTORC1 pathway controls terminal maturation of lysosomes. Biochem Biophys Res Commun, 417, 1151-1157.
95. Bissig C, & amp; Gruenberg J (2013) Lipid sorting and multivesicular endosome biogenesis. Cold Spring Harb Perspect Biol, 5, a016816.
96. Hu G, Antikainen R, Jousilahti P, Kivipelto M, & Tuomilehto J (2008) Total cholesterol and the risk of Parkinson disease. Neurology, 70, 1972-1979.
97. Hu G (2010) Total cholesterol and the risk of Parkinson's disease: A review for some new findings. Parkinsons Dis, 2010, 836962.
98. Powers KM, Smith-Weller T, Franklin GM, Longstreth WTJr, Swanson PD, & Checkoway H (2009) Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord, 15, 47-52.
99. de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, & amp; Breteler MM (2005) Dietary fatty acids and the risk of Parkinson disease: The Rotterdam study. Neurology, 64, 2040-2045.
100. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H, Parkinson Study Group DATATOP, Investigators (2011) Serum cholesterol and the progression of Parkinson's disease: Results from DATATOP. PLoS One, 6, e22854.
101. Marwarha G, & amp; Ghribi O (2015) Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap? Exp Gerontol, 68, 13-18.
102. Cheng D, Jenner AM, Shui G, Cheong WF, Mitchell TW, Nealon JR,KimWS,McCann H,WenkMR,HallidayGM, & amp; Garner B (2011) Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One, 6, e17299.
103. Mutemberezi V, Guillemot-Legris O, & amp; Muccioli GG (2016) Oxysterols: From cholesterol metabolites to key mediators. Prog Lipid Res, 64, 152-169.
104. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Sidén A, Diczfalusy U, & amp; Björkhem I (1996) Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A, 93, 9799-9804.
105. Dias V, Junn E, & amp; Mouradian MM (2013) The role of oxidative stress in Parkinson's disease. J Parkinsons Dis, 3, 461-491.
106. Vaya J, & amp; Schipper HM (2007) Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem, 102, 1727-1737.
107. Infante J, Rodŕ?guez-Rodŕ?guez E, Mateo I, Llorca J, Vázquez-Higuera JL, Berciano J, & amp; Combarros O (2010) Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol Aging, 31, 710-714.
108. Marwarha G, RhenT, SchommerT, & GhribiO(2011) The oxysterol 27-hydroxycholesterol regulates synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors-relevance to Parkinson's disease. J Neurochem, 119, 1119-1136.
109. Cheng D, Kim WS, & amp; Garner B (2008) Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport, 19, 1685-1689.